Text Size

Pilot Study Using a Wireless Motility Capsule

This study has been completed.
Sponsor:
Collaborators:
Tate and Lyle Ingredients France
General Mills Inc.
Information provided by (Responsible Party):
University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01102894
First received: March 24, 2010
Last updated: March 21, 2012
Last verified: March 2012
History of Changes
  Purpose

Research suggests dietary fiber may decrease transit time through the gastrointestinal tract. Research studies traditionally use radio-opaque markers to determine gastric emptying, colonic transit, and whole gut transit time. The SmartPill is a single use pill that can be used to determine gastric emptying, colonic transit, and whole gut transit time without requiring X-rays or fecal collections. Previous studies have found radio-opaque markers and the SmartPill detect the similar transit times.

The purpose of this pilot study is to determine if the SmartPill can detect a change in transit time using a significant dose of dietary fiber.


Condition Intervention
Healthy Adults
 Dietary Supplement: Fiber
Device: SmartPill

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Official Title: Measurement of Whole Gut Transit Time After a Dietary Fiber Treatment Using a Wireless Motility Capsule

Resource links provided by NLM:

MedlinePlus related topics: Dietary Fiber
U.S. FDA Resources

Further study details as provided by University of Minnesota - Clinical and Translational Science Institute:

Primary Outcome Measures:
  • Whole Gut Transit Time [ Time Frame: 5 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Gastrointestinal Tolerance [ Time Frame: Day 4 ] [ Designated as safety issue: No ]
  • Food Intake Diary [ Time Frame: Day 1 ] [ Designated as safety issue: No ]
    24 hour food diary


Enrollment: 10
Study Start Date: August 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Low fiber
Subjects consume a low fiber cereal and swallow the SmartPill device that measures gastrointestinal transit time
 Dietary Supplement: Fiber
Standardized breakfast consisting of one half cup of egg substitute, hot cereal with or without 20 grams of wheat bran, and one half cup of water. After consuming the breakfast subjects swallow the SmartPill which measures gastrointestinal transit time.
Other Name: dietary fiber
Device: SmartPill
SmartPill
Experimental: High fiber
Subjects consume a high fiber cereal along with swallowing the SmartPill device that measures gastrointestinal transit time
 Dietary Supplement: Fiber
Standardized breakfast consisting of one half cup of egg substitute, hot cereal with or without 20 grams of wheat bran, and one half cup of water. After consuming the breakfast subjects swallow the SmartPill which measures gastrointestinal transit time.
Other Name: dietary fiber
Device: SmartPill
SmartPill

Detailed Description:

The ability of a device to track gastrointestinal transit time, including gastric emptying time, was measured in healthy people consuming low and high fiber diets.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy men and women
  • Age 18 - 65
  • Non-smoking
  • Not taking medication
  • Non-dieting
  • BMI 18-30
  • English literacy
  • Ability to swallow the SmartPill

Exclusion Criteria:

  • Do not regularly consume breakfast
  • Food allergies to ingredients fond in study products
  • Dislike of hot cereal
  • BMI <18 or >30
  • Are not weight stable
  • Diagnosed with diabetes, cardiovascular, renal, or hepatic disease
  • Cancer in previous 5 years (except basal cell carinoma of the skin)
  • Any gastrointestinal disease or condition
  • Any gastrointestinal surgeries that alter motility
  • Recent antibiotic usage (< 6 months)
  • recent or concurrent participation in an intervention research study
  • History of drug or alcohol abuse in prior 6 months
  • Use of laxatives, anti-diarrheal, antacids, or medications which alter motility
  • Vegetarians
  • People who eat more than approximately 15 grams of fiber per day
  • Currently consume fiber supplements
  • Women who are pregnant or lactating
  • Women with irregular menstrual cycles
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01102894

Locations
United States, Minnesota
University of Minnesota - McNeal Hall
St. Paul, Minnesota, United States, 55108
Sponsors and Collaborators
University of Minnesota - Clinical and Translational Science Institute
Tate and Lyle Ingredients France
General Mills Inc.
Investigators
Principal Investigator: Joanne L Slavin, PhD University of Minnesota - Clinical and Translational Science Institute
  More Information

No publications provided by University of Minnesota - Clinical and Translational Science Institute

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov Identifier: NCT01102894     History of Changes
Other Study ID Numbers: 0903M60781
Study First Received: March 24, 2010
Last Updated: March 21, 2012
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on May 19, 2013